Fresenius Medical Care heads into its third-quarter report with an unusual problem. The parts of the business management controls most tightly, such as pricing, cost cuts and clinic consolidation, are working better than expected. Patient volume, the one metric that underpins everything else, is slipping in the US, and management has said the cause is the company's own execution rather than the market. The November 3 release, due before the opening bell, will show whether that admission marked a low point or the start of a longer slide.

For context, the dialysis giant earned $0.66 per share on $5.65 billion of revenue last quarter, against $0.64 and $5.71 billion in the year-ago third quarter. That mix of flat-to-lower sales and rising per-share earnings sums up the story well: profitability is growing faster than the business itself. Management reaffirmed full-year guidance in August, so the question this time is less about the annual target and more about how the company reaches it.

The main issue is US same-market treatment growth. It went from slightly positive in the third quarter of last year to roughly flat, then to minus 0.37% in the first quarter and minus 0.9% in the second, with May and June weakening sharply. Management dropped its assumption of a flat year and now expects the full year to land near the second-quarter rate. It blamed a gap in converting accepted referrals into actual patients, which amounts to losing share to competitors. That framing works both ways. A self-inflicted problem can in principle be fixed, but management also said the effect builds through the year and pushed a return to growth into 2027. A third-quarter reading around minus 0.9% would match the revised outlook. A noticeably worse number would suggest the referral problem is spreading faster than the fix. International volume, which slowed to 0.8% growth, its weakest in about two years, also needs to stabilize to keep the slowdown from looking global.

The offsetting story has been strong. Group operating income rose 23% at constant currency last quarter, and care delivery margins expanded by nearly four percentage points. That gain was driven by better rates, improved revenue-cycle management and around 100 clinic closures, not just pharmaceutical reimbursement tailwinds. Value-based care turned profitable, savings from the FME25+ program rose to €67 million, and the 5008X high-volume HDF machine rollout reached 10% of the fleet with a target of about 20% this year. Further margin expansion, savings above the second-quarter pace and evidence that conversions are on schedule would show the margin engine is still running on its own strength. Care enablement deserves close attention as well. Earnings there fell 5% on China regulatory pressure and new Middle East-related cost inflation, and a second decline would test management's claim that those costs are absorbed in guidance.

The market has already formed a view. Shares have fallen 11.2% since the last report while the S&P 500 gained 2.7%, and sentiment has swung from close to neutral heading into August to firmly bearish. The stock, at $23.13, sits barely above its 200-day moving average and roughly in the middle of its post-earnings range of $20.23 to $26.42. That position points to indecision rather than capitulation. The lower bar does help, since steady volume plus continued margin gains would likely surprise a skeptical crowd.

The outcome depends on whether the volume problem stays contained. If US treatment trends hold near the revised outlook while margins, savings and buybacks keep growing earnings, the thesis that self-help can bridge the gap to 2027 remains intact. If volumes deteriorate again, investors will start to question how long cost discipline can make up for a shrinking patient base.